Concord Wealth Partners Harvard Bioscience Inc Transaction History
Concord Wealth Partners
- $591 Million
- Q3 2024
A detailed history of Concord Wealth Partners transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Concord Wealth Partners holds 750 shares of HBIO stock, worth $1,627. This represents 0.0% of its overall portfolio holdings.
Number of Shares
750Holding current value
$1,627% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding HBIO
# of Institutions
96Shares Held
31.5MCall Options Held
700Put Options Held
2.1K-
Black Rock Inc. New York, NY2.84MShares$6.17 Million0.0% of portfolio
-
Punch & Associates Investment Management, Inc. Edina, MN2.77MShares$6.02 Million0.44% of portfolio
-
Harvey Partners, LLC Tarrytown, NY2.72MShares$5.89 Million0.87% of portfolio
-
Amh Equity LTD2.39MShares$5.18 Million8.88% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$4.67 Million0.0% of portfolio
About HARVARD BIOSCIENCE INC
- Ticker HBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 41,636,500
- Market Cap $90.4M
- Description
- Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...